Do Extremely Low Gestational Age Neonates Regulate Iron Absorption via Hepcidin? - 20/01/22
, Bryan A. Comstock, MS 2, Pratik Parikh, MD 3, Dale Whittington, BS 4, Dennis E. Mayock, MD 1, Patrick J. Heagerty, PhD 2, Timothy M. Bahr, MD 5, Sandra E. Juul, MD, PhD 1Abstract |
Objectives |
To evaluate whether extremely preterm infants regulate iron status via hepcidin.
Study design |
In this retrospective analysis of infants from the Preterm Epo Neuroprotection (PENUT) Trial, urine hepcidin (Uhep) normalized to creatinine (Uhep/UCr) was evaluated among infants randomized to erythropoietin (Epo) or placebo.
Results |
The correlation (r) between Uhep/UCr and serum markers of iron status (ferritin and zinc protoporphyrin-to-heme ratio [ZnPP/H]) and iron dose was assessed. A total of 243 urine samples from 76 infants born at 24-276/7 weeks gestation were analyzed. The median Uhep/UCr concentration was 0.3, 1.3, 0.4, and 0.1 ng/mg at baseline, 2 weeks, 4 weeks, and 12 weeks, respectively, in placebo-treated infants. The median Uhep/UCr value in Epo-treated infants were not significantly different, with the exception of the value at the 2-week time point (median Uhep/UCr, 0.1 ng/mg; P < .001). A significant association was seen between Uhep/UCr and ferritin at 2 weeks (r = 0.63; P < .001) and at 4 weeks (r = 0.41; P = .01) and between Uhep/UCr and ZnPP/H at 2 weeks (r = −0.49; P = .002).
Conclusions |
Uhep/UCr values correlate with serum iron markers. Uhep/UCr values vary over time and are affected by treatment with Epo, suggesting that extremely preterm neonates can regulate hepcidin and therefore their iron status. Uhep is suppressed in extremely preterm neonates, particularly those treated with Epo.
Le texte complet de cet article est disponible en PDF.Keywords : iron, preterm, ferritin, zinc protoporphyrin-to-heme ratio, hepcidin
Abbreviations : Epo, IS, IV, PAR, PENUT, Uhep, Uhep/UCr, ZnPP/H
Plan
| Funded by the Marshall Klaus Perinatal Research Award, the University of Washington Institute of Translational Health Sciences Early Investigator Catalyst Award, and the National Institute of Neurological Disorders and Stroke, United States (Grants U01NS077955 and U01NS077953). The sponsors had no involvement in the study design, sample collection, analysis, interpretation of data, writing of the report, or the decision to submit the manuscript for publication. The authors declare no conflicts of interest. |
|
| Portions of this study were presented at the Pediatric Academic Societies meeting, May 2018, Toronto, Canada; and the American Academy of Pediatrics meeting, November 2018, Orlando, Florida. |
Vol 241
P. 62 - février 2022 Retour au numéro
Article précédent
- 50 Years Ago in The Journal of Pediatrics : What’s In a Name: Lessons Learned from Atypical Malformation Syndromes
- Jessica R.C. Priestley, Ian D. Krantz
- Biomarkers of Pulmonary Hypertension Are Altered in Children with Down Syndrome and Pulmonary Hypertension
- Megan Griffiths, Jun Yang, Dhananjay Vaidya, Melanie Nies, Stephanie Brandal, D. Dunbar Ivy, Francis Hickey, Kristine Wolter-Warmerdam, Eric D. Austin, Mary Mullen, Michael W. Pauciulo, Katie A. Lutz, Erika B. Rosenzweig, Russel Hirsch, Delphine Yung, William C. Nichols, Allen D. Everett
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?